What is the interpretation of a positive QuantiFERON Gold (Interferon-Gamma Release Assay) result with a TB1-NIL (Tuberculosis antigen 1 - Negative Control) value of Elevated Interferon-Gamma Response and a TB2-NIL (Tuberculosis antigen 2 - Negative Control) value of Elevated Interferon-Gamma Response, and a Mitogen-NIL (Mitogen - Negative Control) value of Elevated Interferon-Gamma Response?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: May 12, 2025 • View editorial policy

From the Guidelines

You should see a healthcare provider immediately for a chest X-ray and clinical evaluation to determine if you have active TB disease or latent TB infection, as your positive QuantiFERON-TB Gold test results (TB1-NIL 4.3 and TB2-NIL 4.6) indicate infection with tuberculosis (TB) 1. Your specific results show strong immune responses to TB antigens, and your mitogen control (6.5) confirms your immune system is functioning properly.

Key Considerations

  • A positive QuantiFERON-TB Gold test result should prompt the same public health and medical interventions as a positive TST result, according to guidelines 1.
  • Evaluation for TB disease is necessary before latent TB infection (LTBI) can be diagnosed, and this evaluation should include, at a minimum, a chest radiograph to examine for abnormalities consistent with TB disease 1.
  • Additional medical evaluation would depend on clinical judgment based on findings from history, physical examination, and chest radiography, and HIV counseling, testing, and referral is recommended because HIV infection increases the suspicion for TB and the urgency of treating LTBI 1.

Treatment Options

  • If you have no symptoms and normal imaging, you likely have latent TB infection, which requires treatment to prevent future active disease.
  • The recommended treatment is typically isoniazid 300mg daily for 9 months, rifampin 600mg daily for 4 months, or isoniazid plus rifapentine weekly for 12 weeks.
  • Treatment is essential as there's a 5-10% lifetime risk of latent TB progressing to active, contagious TB disease.

Clinical Evaluation

  • Your doctor will ask about TB exposure history, symptoms like cough or fever, and risk factors for progression to active disease during the evaluation.
  • Your strong test response doesn't indicate disease severity but confirms exposure to TB bacteria.

From the Research

Interpretation of Quantiferon Gold Results

  • The Quantiferon Gold test measures the immune response to TB antigens, with results indicating the presence of latent tuberculosis infection (LTBI) 2.
  • A positive result, such as TB1-NIL 4.3 and TB2-NIL 4.6, suggests that the individual has been infected with Mycobacterium tuberculosis 2.
  • The mitogen-nil result of 6.5 indicates a valid test, as it shows a response to the mitogen control 2.

Treatment Options for Latent Tuberculosis Infection

  • Several treatment regimens are available for LTBI, including isoniazid monotherapy, rifampin-based regimens, and combination therapies 3, 4, 5.
  • The choice of treatment regimen depends on various factors, including the individual's medical history, potential drug interactions, and the presence of any contraindications 3, 4.
  • Treatment completion rates and safety profiles vary among the different regimens, with some studies suggesting that shorter regimens, such as 3-month isoniazid-rifapentine, may have higher completion rates and similar efficacy to longer regimens 6.

Monitoring Treatment Response

  • The Quantiferon Gold test is not recommended for monitoring the effect of preventive therapy, as most patients remain positive after treatment 2.
  • Other methods, such as clinical evaluation and laboratory tests, may be used to monitor treatment response and potential side effects 3, 4, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.